Company Reports / Bristol-Myers Squibb

COMPANY: Bristol-Myers Squibb

INDEX RANK: 13th

Total Impact Score: 27,807.22

Bristol-Myers Squibb is ranked 13th place in our index for 2015. Bristol-Myers Squibb’s drugs have a total impact score of 27,807.22. Bristol-Myers Squibb treats two diseases in our model - XDR-TB and HIV - with four total drugs - Amikacin (Amk), Didanosine (ddl), Stavudine (d4t), and Atazanafir/Ritonavir (ATV/r).Bristol-Myers Squibb receives credit for one treatment against XDR-TB - Amikacin (Amk). This drug averted 8863.27 of the total DALYs for XDR-TB, which is 12.5% of the worldwide DALYs that we estimate would be lost to XDR-TB in 2015 in the absence of effective treatment. Bristol-Myers Squibb receives credit for three treatments against HIV - Stavudine (d4t), Atazanafir/Ritonavir (ATV/r), and Didanosine (ddl). These three drugs averted 35007.95 of the total DALYS for HIV, which is 8.98% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. Bristol-Myers Squibb’s drug portfolio placed it 7th in terms of total averted DALYs for HIV.

Company Score Breakdown:

Key Drugs

ATAZANAVIR/RITONAVIR (ATV/R)

Atazanavir/Ritonavir (ATV/r) is an ARV combination drug recommended by the WHO as a part of preferred secondline regimens to treat HIV in adults and adolescents, as part of an alternative 2ndline regimen for children, and as part of the preferred 2nd line regimen when there is an HBV coinfection. Major toxicity concerns include jaundice, nephrolithiasis, and electrocardiographic abnormalities. Atazanavir/ Ritonavir was first patented Bristol-Myers Squibb in 1998.

AMIKACIN (AMK)

Amikacin (Amk), an aminoglycoside antibiotic, is a second-line injectable agent recommended in the treatment of rifampicinresistant and multidrug-resistant tuberculosis. It is proven effective against TB and has a moderate safety profile. Side effects include hearing loss and damage to the kidneys. A patent for Amk was issued to Bristol Myers Squibb in 1973.

DIDANOSINE (DDL)

Didanosine (ddl) is an ARV drug that is no longer recommended, and should be discontinued for use, by the WHO as an alternative medicine in 2nd-line regimens because of toxicity, low efficacy, and inconvenient dosing procedure. However, it can be added as a back-up drug while lacking procurement of more effective ARVs. Didanosine was developed by researchers in the National Cancer Institute(NCI). Due to limitations as a public agency, the NCI granted Bristol-Myers Squibb Co. exclusive rights to market didanosine.

STAVUDINE (D4T)

Stavudine (d4T) is an ARV drug that is no longer recommended for use by the WHO and should be discontinued as a part of HIV treatment regimens due to mitochondrial toxicity. It was first patented by Bristol Myers Squibb.

Company Information

Bristol-Myers Squibb, formed from the merger of Bristol-Myers and Squibb in 1989, is a global pharmaceutical company founded in 1858, currently headquartered in New York, NY. The company manufactures products in the areas of cardiovascular disease, HIV, cancer, diabetes, hepatitis, psychiatric disorders, and rheumatoid arthritis. They are focused on developing and delivering medicines that help patients with serious diseases. BMS’s Global Access Program improves access to three of their HIV medicines through a patent policy that allows for generic manufacturing and zero-profit pricing in low-income countries. Their Secure the Future® initiative, a branch of the Bristol-Myers Squibb foundation, works to alleviate burden from HIV in communities in Africa by offering different kinds of care. Some of their products include Videx®, Evotaz® and Zerit®. In 2017, the company’s revenue was $20.8 billion and they had 23,700 employees.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT